Antibody Response in Healthcare Workers Before and After the Third Dose of Anti-SARS-CoV-2 Vaccine: A Pilot Study

Overview

Journal Vaccines (Basel)

Date 2022 Jun 24

PMID 35746470

Authors

Alessandra Panico

Giambattista Lobreglio

Francesco Bagordo

Antonella Zizza

Antonella De Donno

Chiara Rosato

Roberta Lazzari

Michele Chicone

Floriano Indino

Virginia Recchia

Pietro Alifano

Tiziana Grassi

Affiliations

Soon will be listed here.

Abstract

The SARS-CoV-2 pandemic led to the development of various vaccines. The BNT162b2 mRNA vaccine was the first approved due to its efficacy in eliciting a humoral immunity response after the second dose. However, a decrease in the antibody concentration was observed over time. Therefore, the administration of a third dose was scheduled, primarily for frail people and workers of essential public activities. The aim of this study was to assess the level of antibodies against the spike (S) RBD of SARS-CoV-2 in healthcare workers before and after the third dose of BNT162b2 vaccine, according to sex, age, and the time interval between vaccine doses and tests. All 37 (12 males, 25 females, 19 < 50 years old, 18 ≥ 50 years old) healthcare workers recruited showed a consistent antibody titer increase after the third dose. Data analysis showed that the antibody concentration before the third dose significantly decreased as the time interval up to the test increased, and a significantly higher level was shown in young than older people. Cluster analysis revealed that young females had a higher antibody level than older females before the third dose (p < 0.05). This study indicated the benefit of the third dose of BNT162b2 vaccine and its effect on leveling up the humoral immune response.

Citing Articles

Kinetics of SARS-CoV-2 Viral Load in Hospitalized Patients.

Panico A, Bagordo F, Nolasco E, Grassi T, Bianco A, Indino F Pathogens. 2024; 13(5).

PMID: 38787281 PMC: 11123864. DOI: 10.3390/pathogens13050429.

Factors Associated with Pneumonia in Patients Hospitalized with COVID-19 and the Role of Vaccination.

Zizza A, Sedile R, Bagordo F, Panico A, Guido M, Grassi T Vaccines (Basel). 2023; 11(8).

PMID: 37631910 PMC: 10458032. DOI: 10.3390/vaccines11081342.

Anti-SARS-CoV-2 IgG Antibody Response in Individuals Infected Post Complete Vaccination: A 6-Month Longitudinal Study in Healthcare Professionals.

Baratto N, Maistrello L, Pazienza E, Barresi R Vaccines (Basel). 2023; 11(6).

PMID: 37376466 PMC: 10301235. DOI: 10.3390/vaccines11061077.

Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine.

Grassi T, Lobreglio G, Panico A, Rosato C, Zizza A, Lazzari R Vaccines (Basel). 2022; 10(11).

PMID: 36423043 PMC: 9696835. DOI: 10.3390/vaccines10111948.

Risk management and communication plans from SARS to COVID-19 and beyond.

Recchia V, Aloisi A, Zizza A Int J Health Plann Manage. 2022; 37(6):3039-3060.

PMID: 35983693 PMC: 9559595. DOI: 10.1002/hpm.3545.

References

Gee J, Marquez P, Su J, Calvert G, Liu R, Myers T . First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(8):283-288. PMC: 8344985. DOI: 10.15585/mmwr.mm7008e3. View

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz L, Vormehr M . COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses. Nature. 2020; 586(7830):594-599. DOI: 10.1038/s41586-020-2814-7. View

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View

Ciarambino T, Para O, Giordano M . Immune system and COVID-19 by sex differences and age. Womens Health (Lond). 2021; 17:17455065211022262. PMC: 8188967. DOI: 10.1177/17455065211022262. View

Flanagan K, Fink A, Plebanski M, Klein S . Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. Annu Rev Cell Dev Biol. 2017; 33:577-599. DOI: 10.1146/annurev-cellbio-100616-060718. View

Souza P, Mesquita F, Amaral J, Landim P, Lima K, Costa M . The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape. Int J Biol Macromol. 2022; 208:105-125. PMC: 8920968. DOI: 10.1016/j.ijbiomac.2022.03.058. View

Naaber P, Tserel L, Kangro K, Sepp E, Jurjenson V, Adamson A . Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021; 10:100208. PMC: 8418937. DOI: 10.1016/j.lanepe.2021.100208. View

Libert C, Dejager L, Pinheiro I . The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol. 2010; 10(8):594-604. DOI: 10.1038/nri2815. View

Chodick G, Tene L, Rotem R, Patalon T, Gazit S, Ben-Tov A . The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data. Clin Infect Dis. 2021; 74(3):472-478. PMC: 8240867. DOI: 10.1093/cid/ciab438. View

10.

Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C . Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med. 2021; 385(16):1474-1484. PMC: 8362591. DOI: 10.1056/NEJMoa2109072. View

11.

Haas E, Angulo F, McLaughlin J, Anis E, Singer S, Khan F . Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021; 397(10287):1819-1829. PMC: 8099315. DOI: 10.1016/S0140-6736(21)00947-8. View

12.

Pellini R, Venuti A, Pimpinelli F, Abril E, Blandino G, Campo F . Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine. 2021; 36:100928. PMC: 8177433. DOI: 10.1016/j.eclinm.2021.100928. View

13.

Teixeira D, Longo-Maugeri I, Santos J, Duarte Y, Lebrao M, Bueno V . Evaluation of lymphocyte levels in a random sample of 218 elderly individuals from São Paulo city. Rev Bras Hematol Hemoter. 2012; 33(5):367-71. PMC: 3415787. DOI: 10.5581/1516-8484.20110100. View

14.

Goldberg Y, Mandel M, Bar-On Y, Bodenheimer O, Freedman L, Haas E . Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021; 385(24):e85. PMC: 8609604. DOI: 10.1056/NEJMoa2114228. View

15.

Zimmermann P, Curtis N . Factors That Influence the Immune Response to Vaccination. Clin Microbiol Rev. 2019; 32(2). PMC: 6431125. DOI: 10.1128/CMR.00084-18. View

16.

Fan H, Dong G, Zhao G, Liu F, Yao G, Zhu Y . Gender differences of B cell signature in healthy subjects underlie disparities in incidence and course of SLE related to estrogen. J Immunol Res. 2014; 2014:814598. PMC: 3987971. DOI: 10.1155/2014/814598. View

17.

Klein S, Jedlicka A, Pekosz A . The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010; 10(5):338-49. PMC: 6467501. DOI: 10.1016/S1473-3099(10)70049-9. View

18.

Poland G, Ovsyannikova I, Kennedy R, Lambert N, Kirkland J . A systems biology approach to the effect of aging, immunosenescence and vaccine response. Curr Opin Immunol. 2014; 29:62-8. PMC: 4119552. DOI: 10.1016/j.coi.2014.04.005. View

19.

Gandolfo C, Anichini G, Mugnaini M, Bocchia M, Terrosi C, Sicuranza A . Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine. Vaccines (Basel). 2022; 10(2). PMC: 8879995. DOI: 10.3390/vaccines10020171. View

20.

Levin E, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S . Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021; 385(24):e84. PMC: 8522797. DOI: 10.1056/NEJMoa2114583. View